Swedish Orphan Biovitrum (Sobi) has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics, a move that will expand Sobi’s presence in the gout treatment market. Sobi will purchase for Arthrosi Skr9.1bn ($950m) in cash. Additional payments of up to Skr5.3bn…
Continue reading...